Regulation

Questions answered here

• What criteria does FDA Decision Point D use to evaluate human factors validation data?Decision Point D evaluates whether human factors validation test data must be submitted based on user interface history of use, user interface complexity, and adequacy of existing risk controls. To support this pathway, manufacturers require robust objective evidence, including clean risk analyses, full traceability, known use problems, and connected post-market complaint signals.
• How does FDA human factors guidance differ from IEC 62366-1 for medical devices?While IEC 62366-1 outlines the general usability engineering process, the FDA requires specific US submission criteria. Key differences include expecting at least 15 participants per user group, using US-resident participants, testing US-marketed labelling and training, providing explicit critical task analyses, and following a recommended structure for the human factors engineering report.
• How are critical tasks defined in medical device human factors?Critical tasks are defined by consequence rather than difficulty, occurring when getting a task wrong could cause harm. For medical devices reviewed by the CDRH, critical tasks involve potential serious harm. For combination products reviewed by DMEPA, they cover any potential harm, including underdose, overdose, or missed doses disrupting treatment.
• What are the human factors requirements under the EU MDR?The EU Medical Device Regulation embeds human factors expectations into requirements regarding intended use, reasonably foreseeable misuse, ergonomic characteristics, and use environments. Manufacturers must demonstrate an understanding of real users before designs are fixed, using the IEC 62366-1 framework to connect usability engineering to risk management and provide evidence of safe, effective use.
• Does human factors depend on medical device regulatory class?Human factors is not tied to regulatory classification. Regulators can request evidence of how use-related risks are addressed even for lower-class devices and drug products. While the depth and rigour of the human factors process scale with the risk of harm, applying usability principles ensures safe, effective use and better market adoption.
• How do medical device human factors requirements differ between the FDA, EU MDR, and NMPA?The FDA evaluates whether intended US users can complete critical tasks safely, whilst China's NMPA scrutinises data transferability across local user characteristics and clinical practices. Under EU MDR, Notified Bodies increasingly demand rigorous usability evidence linked to safety and performance. Medical device teams must justify human factors transferability rather than assuming evidence applies globally.
• Does regulation slow down innovation in medical device development?Regulation does not inherently slow innovation; delays happen when teams develop devices without understanding regulatory expectations. Leaving Human Factors until validation leads to reactive fixes and expensive surprises. Companies clear regulation more smoothly by identifying usability risks early, iterating designs, and treating human factors as an integral part of ongoing development.